Conatus Pharmaceuticals Q4 Earnings Outlook

Conatus Pharmaceuticals CNAT announces its next round of earnings Wednesday. Here's Benzinga's advanced look at Conatus Pharmaceuticals' Q4 earnings report.

Earnings and Revenue

Analysts covering Conatus Pharmaceuticals have modeled for quarterly EPS loss of 17 cents per share on revenue of $9.49 million.

Conatus Pharmaceuticals reported a loss of 35 cents when it published results during the same quarter last year. Sales in that period totaled $799,000. If the company were to report inline earnings when it publishes results Wednesday, quarterly profit would be down 51.43 percent. Sales would be have grown 1087.67 percent from the same quarter last year.

Conatus Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past like this:

Stock Performance

Over the last 52-week period, shares of Conatus Pharmaceuticals are up 47.06 percent.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts generally rate Conatus Pharmaceuticals stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Conatus Pharmaceuticals's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.